<DOC>
	<DOCNO>NCT02984982</DOCNO>
	<brief_summary>Primary Objective : To compare efficacy alirocumab standard care coronary atheroma progression patient experience acute coronary syndrome ( ACS ) event treat atorvastatin rosuvastatin . Secondary Objectives : - To compare efficacy alirocumab standard care absolute change percent atheroma volume ( PAV ) normalize total atheroma volume ( TAV ) . - To evaluate efficacy alirocumab low-density lipoprotein cholesterol ( LDL-C ) , apolipoprotein B ( Apo-B ) , triglyceride , non-high-density lipoprotein cholesterol ( non-HDL-C ) Lipoprotein ( ) ( Lp [ ] ) . - To evaluate safety alirocumab include occurrence cardiovascular event ( coronary heart disease [ CHD ] death , non-fatal myocardial infarction [ MI ] , fatal non-fatal ischemic stroke , unstable angina require hospitalization ) .</brief_summary>
	<brief_title>Evaluation Coronary Artery Plaque Volume Progression/Regression Safety Alirocumab Japanese Patients Hospitalized Acute Coronary Syndrome With Hypercholesterolemia</brief_title>
	<detailed_description>The duration study per patient 9 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Bezafibrate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Inclusion criterion : Patients hospitalize ACS ( Acute STsegment elevation myocardial infarction [ STEMI ] , Acute nonSTsegment elevation myocardial infarction [ NSTEMI ] , Unstable angina [ UA ] ) . Low density lipoprotein cholesterol ≥100 mg/dL . Patients undergo Intravascular Ultrasound ( IVUS ) image coronary artery least &gt; 50 % stenosis angiographically within 1 week ACS onset . Patients age ≥20 year old ACS diagnosis . Negative serum Hepatitis B surface antigen , Hepatitis B core antibody , Hepatitis C antibody test . Written informed consent . Exclusion criterion : Patients previously treat least one dose antiproprotein convertase subtilisin/kexin type 9 ( antiPCSK9 ) monoclonal antibody . Uncontrolled hypertension ( multiple read systolic blood pressure [ SBP ] &gt; 180 mmHg diastolic blood pressure [ DBP ] &gt; 110 mmHg ) ACS diagnosis randomization visit . Known history hemorrhagic stroke . Currently treatment cancer . Patients LDL apheresis . Any clinically significant abnormality identify judgment Investigator subInvestigator would preclude safe completion study constrain endpoint assessment major systemic disease , patient short life expectancy . Considered Investigator subInvestigator inappropriate study reason , include : Unable meet specific protocol requirement , schedule visit ; Investigator subInvestigator , pharmacist , study coordinator , study staff relative thereof directly involve conduct protocol , etc ; Presence condition ( eg , geographic , social , etc . ) actual anticipate , Investigator feel would restrict limit patient 's participation duration study . Laboratory finding measure within 2 week ACS diagnosis ( positive serum urine pregnancy test female childbearing potential ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>